Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.13 USD
Change Today +0.18 / 2.01%
Volume 16.5K
TRIV On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

trivascular technologies inc (TRIV) Snapshot

Open
$8.88
Previous Close
$8.95
Day High
$9.51
Day Low
$8.35
52 Week High
06/3/14 - $17.99
52 Week Low
04/15/15 - $7.84
Market Cap
186.2M
Average Volume 10 Days
158.7K
EPS TTM
--
Shares Outstanding
20.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRIVASCULAR TECHNOLOGIES INC (TRIV)

Related News

No related news articles were found.

trivascular technologies inc (TRIV) Related Businessweek News

No Related Businessweek News Found

trivascular technologies inc (TRIV) Details

TriVascular Technologies, Inc., a medical device company, develops and commercializes technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The company offers Ovation System, a stent graft platform for the treatment of AAA through minimally invasive endovascular aortic repair. Its ovation system components include arotic body, iliac limbs, and fill polymer. The company markets and sells its products through direct sales organizations in the United States, Germany, the United Kingdom, the Netherlands, and Canada, as well as through distributors or agents in other markets. TriVascular Technologies, Inc. was incorporated in 2007 and is headquartered in Santa Rosa, California.

307 Employees
Last Reported Date: 03/9/15
Founded in 2007

trivascular technologies inc (TRIV) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.0K
Co-Founder and Chief Technology Officer
Total Annual Compensation: $296.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $356.2K
Compensation as of Fiscal Year 2014.

trivascular technologies inc (TRIV) Key Developments

TriVascular Technologies, Inc. Provides Preliminary Unaudited Revenue Guidance for the First Quarter and Full Year of 2015

TriVascular Technologies, Inc. provided preliminary unaudited revenue guidance for the first quarter and full year of 2015. For the quarter, the company expects total revenue of approximately $8.0 million for the first quarter of 2015, an increase of 14.1% from the first quarter of 2014. Total revenue growth on a constant currency basis was 19.3% in the first quarter 2015. Underlying implant growth exceeded 25% in the United States and internationally. The company currently anticipates total revenue for full-year 2015 to be in the range of $36 to $39 million which represents a range of 13% to 23% year over year growth on an as reported basis and 17% to 27% year over year growth on a constant currency basis.

TriVascular Technologies, Inc. Auditor Raises 'Going Concern' Doubt

TriVascular Technologies, Inc. filed its 10-K on Mar 09, 2015 for the period ending Dec 31, 2014. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

TriVascular Technologies, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

TriVascular Technologies, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $9,088,000 compared to $6,235,000 a year ago. Loss from operations was $12,526,000 compared to $11,782,000 a year ago. Loss before income tax expense was $14,344,000 compared to $13,339,000 a year ago. Net loss was $14,491,000 compared to $13,489,000 a year ago. Basic and diluted net loss per share was $0.72 compared to $23.36 a year ago. LBITDA was $12,437,000 compared to $11,550,000 a year ago. Adjusted LBITDA was $11,764,000 compared to $11,302,000 a year ago. For the full year, the company reported revenue of $31,798,000 compared to $19,508,000 a year ago. Loss from operations was $50,001,000 compared to $43,895,000 a year ago. Loss before income tax expense was $57,061,000 compared to $50,109,000 a year ago. Net loss was $57,373,000 compared to $50,308,000 a year ago. Basic and diluted net loss per share was $3.95 compared to $87.42 a year ago. LBITDA was $48,883,000 compared to $42,723,000 a year ago. Adjusted LBITDA was $48,381,000 compared to $42,336,000 a year ago. The company provided earnings guidance for the full year of 2015. For the period, the company anticipates revenue to be in the range of $45 million to $49 million, reflecting year-over-year growth of approximately 42% to 54% over 2014.  Gross margin is expected to be between 63% and 65%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRIV:US $9.13 USD +0.18

TRIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $18.40 USD +0.24
CR Bard Inc $171.06 USD +0.19
Endologix Inc $17.36 USD -0.05
Lombard Medical Inc $4.12 USD 0.00
St Jude Medical Inc $67.76 USD -0.52
View Industry Companies
 

Industry Analysis

TRIV

Industry Average

Valuation TRIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRIVASCULAR TECHNOLOGIES INC, please visit www.trivascular.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.